Synthesis of novel highly functionalized biologically active polycyclic caged amides

Tetrahedron Letters

Volumn 48, Issue 35, 2007, Pages 6204-6208

  James, Beena ^a   Viji, S ^a   Mathew, Soumini ^a   Nair, Mangalam S ^a   Lakshmanan, Divya ^b   Ajay Kumar, R ^b  

^a REGIONAL RESEARCH LABORATORY CSIR   (India)

^b RAJIV GANDHI CENTRE FOR BIOTECHNOLOGY   (India)

Author keywords

[No Author keywords available]

Indexed keywords

1,9 BIS(BROMOMETHYL)PENTACYCLO[5.4.0.0 2,6 .0 3,10 .0 5,9 ]UNDECA 8,11 DIONE; 1,9 BIS(CHLOROMOMETHYL)PENTACYCLO[5.4.0.0 2,6 .0 3,10 .0 5,9 ]UNDECA 8,11 DIONE; 3 BROMOMETHYL 4 (N DIETHYLCARBAMOYL)TETRACYCLO[4.2.1.1 3,8 .0 2,5 ]DEC 7(11) EN 10 ONE; 3 CHLOROMETHYL 4 (N DIPROPYLCARBAMOYL)TETRACYCLO[4.2.1.1 3,8 .0 2,5 ]DEC 7(11) EN 10 ONE; 7 BROMOMETHYL 8 (N DIETHYLCARBAMOYL)TETRACYCLO[4.2.1.1 4,7 .0 2,5 ]DEC 3(11) EN10 ONE; 7 BROMOMETHYL 8 (N DIMETHYLCARBAMOYL)TETRACYCLO[4.2.1.1 4,7 .0 2,5 ]DEC 3(11) EN 10 ONE; 7 CHLOROMETHYL 8 (N DIMETHYLCARBAMOYL)TETRACYCLO[4.2.1.1 4,7 .0 2,5 ]DEC 3(11) EN 10 ONE; 7 CHLOROMETHYL 8 (PYRROLIDINECARBAMOYL)TETRACYCLO[4.2.1.1 4,7 .0 2,5 ]DEC 3(11) EN 10 ONE; AMINE; BISHALOMETHYL PENTACYCLO UNDECANE DIONE; IONIC LIQUID; POLYCYCLIC AMIDE; POLYCYCLIC HYDROCARBON; TUBERCULOSTATIC AGENT; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DRUG MECHANISM; DRUG SYNTHESIS; NONHUMAN;

EID: 34547594517     PISSN: 00404039     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.tetlet.2007.06.125     Document Type: Article

References (36)

1. Geldenhuys W.J., Malan S.F., Bloomquist J.R., Marchand A.P., and Van der Schyf C.J. Med. Res. Rev. 25 (2005) 21
2. Kroemer R.T., Koutsilieri E., Hecht P., Liedl K.R., and Kornhuber J.J. Med. Chem. 41 (1998) 393
3. Geldenhuys W.J., Malan S.F., Muruges T., Van der Schyf C.J., and Bloomquist J.R. Bioorg. Med. Chem. 12 (2004) 1799
4. Janin Y.L. Bioorg. Med. Chem. 15 (2007) 2479
5. Frieden T.R., Sterling T.R., Munsiff S.S., Watt C.J., and Dye C. Lancet 362 (2003) 887
6. Lee R.E., Protopopova M., Crooks E., Slayden R.A., Terrot M., and Barry III C.E. J. Comb. Chem. 5 (2003) 172
7. Bogatcheva E., Hanrahan C., Nikonenko B., Samala R., Chen P., Gearhart J., Barbosa F., Einck L., Nancy C.A., and Protopopova M. J. Med. Chem. 49 (2006) 3045
8. Jia L., Tomaszewski J.E., Hanrahan C., Coward L., Noker P., Gorman G., Nikonenko B., and Protopopova M. Br. J. Pharmacol. 144 (2005) 80
9. Davis W.L., Grunert R.R., Haff R.F., McGahen J.W., Neumayer E.M., Paulshock M., Watts J.C., Wood T.R., and Hoffmann E.C. Science (1964) 862
10. Schwab R.S., England Jr. A.C., Poskanzer D.C., and Young R.R. J. Am. Med. Assoc. 208 (1969) 1168
11. Danysz W., Parsons C.G., Kornhuber J., Schmidt W.J., and Quack G. Neurosci. Biobehav. Rev. 21 (1997) 455
12. Parsons C.G., Danysz W., and Quack G. Neuropharmacol. 38 (1999) 735
13. Brouillet E., and Beal M.F. Neuroreport 4 (1993) 387
14. Wenk G.L., Danysz W., and Mobley S.L. Eur. J. Pharm. Environ. 293 (1995) 267
15. Geldenhuys W.J., Blanche G.T., Malan C.J., and Van der Schyf S.F. Eur. J. Pharmacol. 458 (2003) 73
16. Oliver D.W., Dekker T.G., Snyckers F.O., and Fourie T.G. J. Med. Chem. 34 (1991) 851
17. Oliver D.W., Dekker T.G., and Snyckers F.O. Drug. Res. 41 (1991) 549
18. Oliver D.W., Dekker T.G., and Snyckers F.O. Eur. J. Med. Chem. 26 (1991) 375
19. Zah J., Blanche G.T., Erasmus E., and Malan S.F. Bioorg. Med. Chem. 11 (2003) 3569
20. Grobler E., Grobler A., Van der Schyf C.J., and Malan S.F. Bioorg. Med. Chem. 14 (2006) 1176
21. Van der Schyf C.J., Squier G.J., and Coetzee W.A. Pharmacol. Res. 18 (1986) 407
22. Malan S.F., Van den Heever I., and Van der Schyf C.J. J. Pharm. Med. 6 (1996) 125
23. Malan S.F., Van der Walt J.J., and Van der Schyf C.J. Arch. Pharm. Pharm. Med. Chem. 333 (2000) 10
24. Malan S.F., Dyason K., Wagenaar B., Van der Walt J.J., and Van der Schyf C.J. Arch. Pharm. Pharm. Med. Chem. 2 (2003) 127
25. Mdzinarishvili A., Geldenhuys W.J., Abbruscato T.J., Bickel U., Klein J., and Van der Schyf C.J. Neurosci. Lett. 383 (2005) 49
26. Van der Schyf C.J., Dekker T.G., and Snyckers F.O. Arch. Pharm. 319 (1986) 409
27. Giannis A., and Kolter T. Angew. Chem., Int. Ed. Engl. (1993) 1267
28. Gante J. Angew. Chem., Int. Ed. Engl. 33 (1994) 1699
29. Marchand A.P., Arney Jr. B.E., Dave P.R., Satyanarayana N., Watson W.H., and Nagl A. J. Org. Chem. 53 (1988) 2644-2647
30. Marchand A.P., Dave P.R., Satyanarayana N., and Arney Jr. B.E. J. Org. Chem. 53 (1988) 1088
31. Nair M.S., Sudhir U., and Rath N.P. Tetrahedron 57 (2001) 7749
32. Nair M.S., Sudhir U., Joly S., and Rath N.P. Tetrahedron 55 (1999) 7653
33. Jain N., Kumar A., Chauhan S., and Chauhan S.M.S. Tetrahedron 61 (2005) 1015
34. James B., Rath N.P., Suresh E., and Nair M.S. Tetrahedron Lett. 47 (2006) 5775
35. Antimycobacterial activity screening by Resazurin Assay: M. tuberculosis H37Rv was grown in Middlebrook 7H9 broth (Difco BBL, Sparks, MD, USA) supplemented with 10% OADC (Becton Dickinson, Sparks, MD, USA). The culture was diluted to McFarland 1 standard with the same medium. From this, 50 μl of this culture was added to 450 μl of fresh medium in 2 ml microcentrifuge tubes. Stock solutions (2 mg/ml) of the test compounds were prepared in dimethylformamide (DMF). The compounds were tested at 1, 10 and 50 μg/ml concentrations. Control tubes had the same volumes of DMF without any substrate. After incubation at 37 °C for 7 days, 20 μl of 0.01% Resazurin (Sigma, St. Louis. MO, USA) in water was added to each tube. Resazurin, a redox dye, is blue in the oxidized state and turns pink when reduced by the growth of viable cells. The control tubes showed a colour change from blue to pink after 24 h at 37 °C. Compounds which prevented the change of colour of the dye were considered to be inhibitory to M. tuberculosis.
36. 3): ...